- Home
- PVL vs PRLD Comparison
PVL vs PRLD Comparison
Compare PVL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- PRLD
- Stock Information
- Founded
- PVL 2011
- PRLD 2016
- Country
- PVL United States
- PRLD United States
- Employees
- PVL N/A
- PRLD N/A
- Industry
- PVL Oil & Gas Production
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- PVL Energy
- PRLD Health Care
- Exchange
- PVL Nasdaq
- PRLD Nasdaq
- Market Cap
- PVL 47.9M
- PRLD 50.1M
- IPO Year
- PVL N/A
- PRLD 2020
- Fundamental
- Price
- PVL $1.55
- PRLD $0.91
- Analyst Decision
- PVL
- PRLD Strong Buy
- Analyst Count
- PVL 0
- PRLD 2
- Target Price
- PVL N/A
- PRLD $4.50
- AVG Volume (30 Days)
- PVL 64.5K
- PRLD 112.9K
- Earning Date
- PVL 01-01-0001
- PRLD 05-06-2025
- Dividend Yield
- PVL 5.81%
- PRLD N/A
- EPS Growth
- PVL N/A
- PRLD N/A
- EPS
- PVL 0.09
- PRLD N/A
- Revenue
- PVL $4,339,313.00
- PRLD $7,000,000.00
- Revenue This Year
- PVL N/A
- PRLD N/A
- Revenue Next Year
- PVL N/A
- PRLD N/A
- P/E Ratio
- PVL $18.60
- PRLD N/A
- Revenue Growth
- PVL N/A
- PRLD N/A
- 52 Week Low
- PVL $1.03
- PRLD $0.61
- 52 Week High
- PVL $1.96
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- PVL 57.44
- PRLD 58.87
- Support Level
- PVL $1.45
- PRLD $0.73
- Resistance Level
- PVL $1.63
- PRLD $1.08
- Average True Range (ATR)
- PVL 0.06
- PRLD 0.10
- MACD
- PVL 0.01
- PRLD 0.01
- Stochastic Oscillator
- PVL 63.04
- PRLD 68.77
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production the sale of oil and natural gas production from primarily non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.